Table 1 Patient’s demographics and clinical characteristics at baselinea as a function of azithromycin treatment response
From: Azithromycin and the microbiota of cystic fibrosis sputum
| Â | Relative | ||
|---|---|---|---|
Responder (n = 17) | Non-Responder (n = 21) | P-value | |
Demographicsb | |||
 Sex (Male:Female) | 7:10 | 7:14 | 0.739 |
 Age (years) | 26.06 (21.9–29.9) | 25.2 (20.7–30.4) | 0.964 |
 ∆F508 / ∆F508 | 9 (52.9) | 10 (47.6) | 1 |
 FEV1% predicted | 44 (32–62) | 56 (40–78) | 0.270 |
 FVC % predicted | 71 (64–87) | 87 (67–99) | 0.171 |
 Body mass index (kg/m2) | 20.1 (18.8–21.4) | 20.6 (18.9–22.1) | 0.402 |
CF related diseasesb | |||
 Pancreatic sufficiency | 2 (11.7) | 3 (14.2) | 1 |
 CF-related diabetes | 4 (23.5) | 1 (4.7) | 0.152 |
 CF-liver disease | 4 (23.5) | 2 (9.5) | 0.378 |
 Osteopenia/Osteoporosis | 5 (29.4) | 10 (47.6) | 0.326 |
Cultured pathogenb | |||
 Pseudomonas aeruginosa | 13 (76.4) | 15 (71.4) | 1 |
 Staphylococcus aureus | 6 (35.2) | 7 (33.3) | 1 |
 Haemophilus influenzae | 1 (5.8) | 1 (4.7) | 1 |
 Stenotrophomonas maltophilia | 2 (11.7) | 1 (4.7) | 0.576 |
 Escherichia coli | 1 (5.8) | 1 (4.7) | 1 |
Therapiesb | |||
 Inhaled DNase | 12 (70.5) | 12 (57.1) | 0.506 |
 Inhaled colistin | 0 (0) | 1 (4.7) | 1 |
 Inhaled tobramycin | 6 (35.2) | 7 (33.3) | 1 |
 Inhaled hypertonic saline | 5 (29.4) | 9 (42.8) | 0.506 |
 Proton pump inhibitor | 4 (23.5) | 9 (42.8) | 0.307 |
 Inhaled corticosteroids | 15 (88.2) | 9 (42.8) | 0.006 |
 Long-acting bronchodilator | 16 (94.1) | 17 (80.9) | 0.355 |
 Short-acting bronchodilator | 12 (70.5) | 15 (71.4) | 1 |
 Pancreatic enzymes | 15 (88.2) | 18 (85.7) | 1 |
 Ranitidine | 4 (23.5) | 1 (4.7) | 0.152 |
 CFTR-modulator | 0 (0) | 0 (0) | – |